Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Inclusion Criteria: * Aneurysmal SAH confirmed with vascular imaging * Aneurysm treated with endovascular or microsurgical intervention * Hunt-Hess ≤ 4 * Modified Fisher Grade I-IV * Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated * First dose of drug can be administered within 24 hours of symptom onset * Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1 * Informed consent obtained by patient or legal authorized representative (LAR) Exclusion Criteria: * Previous hypersensitivity to or treatment with deferoxamine * Presence of giant aneurysm (\>25 mm in size) * Known severe iron deficiency anemia, Hemoglobin (Hgb) g/dl ≤ 7 or transfusion dependent * Irreversibly impaired brainstem function * Abnormal renal function, Serum Creatinine\> 2 mg/dL * Pre-existing severe disability, mRS ≥ 2 * Coagulopathy, including use of anti-platelet or anticoagulant drugs * Known severe hearing loss * Chronic pulmonary disease that limits basic activities of daily living at baseline, or requires the use of home oxygen. * Acute pulmonary disease with the need for any of the following - in a 72 hour period prior to enrollment: \>4L/minute nasal cannula (or equivalent O2 delivery via face mask/ tent), heated-high flow nasal cannula, noninvasive positive pressure ventilation, and in intubated patients FiO2\>45% or positive end-expiratory pressure (PEEP) \> 8cmH2O. This does not include the use of supplemental oxygen in any form for pre-oxygenation, apneic oxygenation, or peri-procedural support alone. * Taking iron supplements containing \> 325 mg of ferrous iron * Pregnancy or nursing * Life expectancy less than 90 days due to co-morbidities * Concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed * Prior history of hepatic dysfunction * Known cytopenia (platelets \< 50,000, Absolute neutrophil count \< 500) * Current use of prochlorperazine * History of severe psychiatric disorder